Skip to main content
PMC home page
Annals of Surgery logoLink to Annals of Surgery
. 1998 Dec;228(6):756–762. doi: 10.1097/00000658-199812000-00006

Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen)

M Lorenz, H H Müller, H Schramm, H J Gassel, H G Rau, K Ridwelski, J Hauss, R Stieger, K W Jauch, W O Bechstein, A Encke
PMCID: PMC1191593  PMID: 9860474

Abstract

OBJECTIVE: To determine the impact of adjuvant hepatic arterial infusion (HAI) on survival relative to resection alone in patients with radical resection of colorectal liver metastases. SUMMARY BACKGROUND DATA: Nearly 40% to 50% of all patients with colorectal carcinoma develop liver metastases. Curative resection results in a 5-year survival rate of 25% to 30%. Intrahepatic recurrence occurs after a median of 9 to 12 months in up to 60% of patients. The authors hypothesized that adjuvant intraarterial infusion of 5-fluorouracil (5-FU) might decrease the rate of intrahepatic recurrence and improve survival in patients with radical resection of colorectal liver metastases. METHODS: Between April 5, 1991, and December 31, 1996, patients with colorectal liver metastases from 26 hospitals were stratified by the number of metastases and the site of the primary tumor and randomized to resection of the liver metastases followed by adjuvant HAI of 5-FU (1000 mg/m2 per day for 5 days as a continuous 24-hour infusion) plus folinic acid (200 mg/m2 per day for 5 days as a short infusion), or liver resection only. RESULTS: The first planned intention-to-treat interim analysis after inclusion of 226 patients and 91 events (deaths) showed a median survival of 34.5 months for patients with adjuvant therapy versus 40.8 months for control patients. The median time to progression was 14.2 months for the chemotherapy group versus 13.7 months for the control group. Grade 3 and 4 toxicities (World Health Organization), mainly stomatitis (57.6%) and nausea (55.4%), occurred in 25.6% of cycles and 62.9% of patients. CONCLUSION: According to this planned interim analysis, adjuvant HAI, when used in this dose and schedule in patients with resection of colorectal liver metastases, reduced the risk of death at best by 15%, but at worst the risk of death was doubled. Thus, the chance of detecting an expected 50% improvement in survival by the use of HAI was only 5%. Patient accrual was therefore terminated.

Full text

PDF
762

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ackerman N. B., Lien W. M., Kondi E. S., Silverman N. A. The blood supply of experimental liver metastases. I. The distribution of hepatic artery and portal vein blood to "small" and "large" tumors. Surgery. 1969 Dec;66(6):1067–1072. [PubMed] [Google Scholar]
  2. Adson M. A., van Heerden J. A., Adson M. H., Wagner J. S., Ilstrup D. M. Resection of hepatic metastases from colorectal cancer. Arch Surg. 1984 Jun;119(6):647–651. doi: 10.1001/archsurg.1984.01390180015003. [DOI] [PubMed] [Google Scholar]
  3. Archer S. G., Gray B. N. Vascularization of small liver metastases. Br J Surg. 1989 Jun;76(6):545–548. doi: 10.1002/bjs.1800760607. [DOI] [PubMed] [Google Scholar]
  4. August D. A., Sugarbaker P. H., Ottow R. T., Gianola F. J., Schneider P. D. Hepatic resection of colorectal metastases. Influence of clinical factors and adjuvant intraperitoneal 5-fluorouracil via Tenckhoff catheter on survival. Ann Surg. 1985 Feb;201(2):210–218. doi: 10.1097/00000658-198502000-00013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bengmark S., Hafström L., Jeppsson B., Jönsson P. E., Rydén S., Sundqvist K. Metastatic disease in the liver from colorectal cancer: an appraisal of liver surgery. World J Surg. 1982 Jan;6(1):61–65. doi: 10.1007/BF01656374. [DOI] [PubMed] [Google Scholar]
  6. Butler J., Attiyeh F. F., Daly J. M. Hepatic resection for metastases of the colon and rectum. Surg Gynecol Obstet. 1986 Feb;162(2):109–113. [PubMed] [Google Scholar]
  7. Cady B., Monson D. O., Swinton N. W. Survival of patients after colonic resection for carcinoma with simultaneous liver metastases. Surg Gynecol Obstet. 1970 Oct;131(4):697–700. [PubMed] [Google Scholar]
  8. Campbell K. A., Burns R. C., Sitzmann J. V., Lipsett P. A., Grochow L. B., Niederhuber J. E. Regional chemotherapy devices: effect of experience and anatomy on complications. J Clin Oncol. 1993 May;11(5):822–826. doi: 10.1200/JCO.1993.11.5.822. [DOI] [PubMed] [Google Scholar]
  9. Cunliffe W. J., Sugarbaker P. H. Gastrointestinal malignancy: rationale for adjuvant therapy using early postoperative intraperitoneal chemotherapy. Br J Surg. 1989 Oct;76(10):1082–1090. doi: 10.1002/bjs.1800761030. [DOI] [PubMed] [Google Scholar]
  10. Curley S. A., Chase J. L., Roh M. S., Hohn D. C. Technical considerations and complications associated with the placement of 180 implantable hepatic arterial infusion devices. Surgery. 1993 Nov;114(5):928–935. [PubMed] [Google Scholar]
  11. Curley S. A., Hohn D. C., Roh M. S. Hepatic artery infusion pumps: cannulation techniques and other surgical considerations. Langenbecks Arch Chir. 1990;375(2):119–124. doi: 10.1007/BF00713397. [DOI] [PubMed] [Google Scholar]
  12. Curley S. A., Roh M. S., Chase J. L., Hohn D. C. Adjuvant hepatic arterial infusion chemotherapy after curative resection of colorectal liver metastases. Am J Surg. 1993 Dec;166(6):743–748. doi: 10.1016/s0002-9610(05)80691-9. [DOI] [PubMed] [Google Scholar]
  13. Demets D. L. Group sequential procedures: calendar versus information time. Stat Med. 1989 Oct;8(10):1191–1198. doi: 10.1002/sim.4780081003. [DOI] [PubMed] [Google Scholar]
  14. Ekberg H., Tranberg K. G., Andersson R., Lundstedt C., Hägerstrand I., Ranstam J., Bengmark S. Determinants of survival in liver resection for colorectal secondaries. Br J Surg. 1986 Sep;73(9):727–731. doi: 10.1002/bjs.1800730917. [DOI] [PubMed] [Google Scholar]
  15. Elias D., Lasser P., Rougier P., Nitenberg G., Théodore C., Lumbroso J. Early adjuvant intraportal chemotherapy after curative hepatectomy for colorectal liver metastases--a pilot study. Eur J Surg Oncol. 1987 Jun;13(3):247–250. [PubMed] [Google Scholar]
  16. Fong Y., Cohen A. M., Fortner J. G., Enker W. E., Turnbull A. D., Coit D. G., Marrero A. M., Prasad M., Blumgart L. H., Brennan M. F. Liver resection for colorectal metastases. J Clin Oncol. 1997 Mar;15(3):938–946. doi: 10.1200/JCO.1997.15.3.938. [DOI] [PubMed] [Google Scholar]
  17. Fortner J. G., Silva J. S., Cox E. B., Golbey R. B., Gallowitz H., Maclean B. J. Multivariate analysis of a personal series of 247 patients with liver metastases from colorectal cancer. II. Treatment by intrahepatic chemotherapy. Ann Surg. 1984 Mar;199(3):317–324. doi: 10.1097/00000658-198403000-00011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Hohenberger P., Schlag P., Schwarz V., Herfarth C. Tumor recurrence and options for further treatment after resection of liver metastases in patients with colorectal cancer. J Surg Oncol. 1990 Aug;44(4):245–251. doi: 10.1002/jso.2930440411. [DOI] [PubMed] [Google Scholar]
  19. Hughes K. S., Simon R., Songhorabodi S., Adson M. A., Ilstrup D. M., Fortner J. G., Maclean B. J., Foster J. H., Daly J. M., Fitzherbert D. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. Surgery. 1986 Aug;100(2):278–284. [PubMed] [Google Scholar]
  20. Iwatsuki S., Esquivel C. O., Gordon R. D., Starzl T. E. Liver resection for metastatic colorectal cancer. Surgery. 1986 Oct;100(4):804–810. [PMC free article] [PubMed] [Google Scholar]
  21. Lindemann F., Schlimok G., Dirschedl P., Witte J., Riethmüller G. Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients. Lancet. 1992 Sep 19;340(8821):685–689. doi: 10.1016/0140-6736(92)92230-d. [DOI] [PubMed] [Google Scholar]
  22. Lorenz M., Staib-Sebler E., Rossion I., Koch B., Gog C., Encke A. Ergebnisse der Resektion und adjuvanten Therapie von Lebermetastasen kolorektaler Primärtumoren--eine Literaturübersicht. Zentralbl Chir. 1995;120(10):769–779. [PubMed] [Google Scholar]
  23. Moertel C. G., Fleming T. R., Macdonald J. S., Haller D. G., Laurie J. A., Goodman P. J., Ungerleider J. S., Emerson W. A., Tormey D. C., Glick J. H. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990 Feb 8;322(6):352–358. doi: 10.1056/NEJM199002083220602. [DOI] [PubMed] [Google Scholar]
  24. Moriya Y., Sugihara K., Hojo K., Makuuchi M. Adjuvant hepatic intra-arterial chemotherapy after potentially curative hepatectomy for liver metastases from colorectal cancer: a pilot study. Eur J Surg Oncol. 1991 Oct;17(5):519–525. [PubMed] [Google Scholar]
  25. Müller H. H., Schäfer H. Regionale adjuvante Therapie bei kolorektalen Lebermetastasen: Anforderungen an klinische Therapiestudien aus statistischer Sicht. Zentralbl Chir. 1995;120(10):755–759. [PubMed] [Google Scholar]
  26. Müller J. M., Schmidt A., Strauss J. M., Zieren H. U. Resektion von Lebermetastasen kolorektaler Karzinome. Anspruch und Wirklichkeit. Dtsch Med Wochenschr. 1991 May 3;116(18):681–688. doi: 10.1055/s-2008-1063665. [DOI] [PubMed] [Google Scholar]
  27. Nordlinger B., Guiguet M., Vaillant J. C., Balladur P., Boudjema K., Bachellier P., Jaeck D. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie. Cancer. 1996 Apr 1;77(7):1254–1262. [PubMed] [Google Scholar]
  28. Nordlinger B., Quilichini M. A., Parc R., Hannoun L., Delva E., Huguet C. Hepatic resection for colorectal liver metastases. Influence on survival of preoperative factors and surgery for recurrences in 80 patients. Ann Surg. 1987 Mar;205(3):256–263. doi: 10.1097/00000658-198703000-00007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. O'Connell M. J., Adson M. A., Schutt A. J., Rubin J., Moertel C. G., Ilstrup D. M. Clinical trial of adjuvant chemotherapy after surgical resection of colorectal cancer metastatic to the liver. Mayo Clin Proc. 1985 Aug;60(8):517–520. doi: 10.1016/s0025-6196(12)60567-9. [DOI] [PubMed] [Google Scholar]
  30. Panis Y., Ribeiro J., Chrétien Y., Nordlinger B. Dormant liver metastases: an experimental study. Br J Surg. 1992 Mar;79(3):221–223. doi: 10.1002/bjs.1800790309. [DOI] [PubMed] [Google Scholar]
  31. Patt Y. Z., McBride C. M., Ames F. C., Claghorn L. J., Cleary K. R., Boddie A. W., Charnsangavej C., Mavligit G. M. Adjuvant perioperative hepatic arterial mitomycin C and floxuridine combined with surgical resection of metastatic colorectal cancer in the liver. Cancer. 1987 Mar 1;59(5):867–873. doi: 10.1002/1097-0142(19870301)59:5<867::aid-cncr2820590502>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  32. Petrelli N. J., Nambisan R. N., Herrera L., Mittelman A. Hepatic resection for isolated metastasis from colorectal carcinoma. Am J Surg. 1985 Feb;149(2):205–209. doi: 10.1016/s0002-9610(85)80065-9. [DOI] [PubMed] [Google Scholar]
  33. Schalhorn A., Kühl M. Pharmakologie der regionalen Chemotherapie kolorektaler Lebermetastasen. Zentralbl Chir. 1995;120(10):764–768. [PubMed] [Google Scholar]
  34. Scheele J., Stang R., Altendorf-Hofmann A., Paul M. Resection of colorectal liver metastases. World J Surg. 1995 Jan-Feb;19(1):59–71. doi: 10.1007/BF00316981. [DOI] [PubMed] [Google Scholar]
  35. Scheele J., Stangl R., Altendorf-Hofmann A., Gall F. P. Indicators of prognosis after hepatic resection for colorectal secondaries. Surgery. 1991 Jul;110(1):13–29. [PubMed] [Google Scholar]
  36. Schoenfeld D. A., Richter J. R. Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint. Biometrics. 1982 Mar;38(1):163–170. [PubMed] [Google Scholar]
  37. Seifert J. K., Junginger T. Resektion von Lebermetastasen kolorektaler Tumoren. Eine uni- und multivariate Analyse von Prognosefaktoren. Langenbecks Arch Chir. 1996;381(4):187–200. doi: 10.1007/BF00571684. [DOI] [PubMed] [Google Scholar]
  38. Wagman L. D., Kemeny M. M., Leong L., Terz J. J., Hill L. R., Beatty J. D., Kokal W. A., Riihimaki D. U. A prospective, randomized evaluation of the treatment of colorectal cancer metastatic to the liver. J Clin Oncol. 1990 Nov;8(11):1885–1893. doi: 10.1200/JCO.1990.8.11.1885. [DOI] [PubMed] [Google Scholar]
  39. Watkins E., Jr, Khazei A. M., Nahra K. S. Surgical basis for arterial infusion chemotherapy of disseminated carcinoma of the liver. Surg Gynecol Obstet. 1970 Apr;130(4):581–605. [PubMed] [Google Scholar]
  40. Wolmark N., Rockette H., Fisher B., Wickerham D. L., Redmond C., Fisher E. R., Jones J., Mamounas E. P., Ore L., Petrelli N. J. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol. 1993 Oct;11(10):1879–1887. doi: 10.1200/JCO.1993.11.10.1879. [DOI] [PubMed] [Google Scholar]

Articles from Annals of Surgery are provided here courtesy of Lippincott, Williams, and Wilkins

RESOURCES